ARL4A: A Potential Drug Target and Biomarker (G10124)

Target Name: ARL4A

NCBI ID: G10124

ARL4A

ARL4A: A Potential Drug Target and Biomarker

ARL4A, also known as ARL4, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the androgen signaling pathway in mammals, and its dysfunction has been linked to various diseases, including cancer, infertility, and neurodegenerative disorders. In this article, we will discuss the potential drug target of ARL4A, its function as a biomarker, and its current research status.

Potential Drug Target

ARL4A is a key regulator of the androgen signaling pathway, which plays a crucial role in the development and maintenance of male sexual function, hair growth, and bone density. In addition, it is involved in the regulation of cell proliferation, apoptosis, and angiogenesis. Therefore, ARL4A is a promising drug target for the treatment of androgen-related diseases, such as androgen-sensitive prostate cancer, male pattern baldness, and testicular infertility.

Biomarker

ARL4A has also been identified as a potential biomarker for various diseases, including cancer, infertility, and neurodegenerative disorders. Its expression has been observed in various types of cancer, including prostate cancer, breast cancer, and colorectal cancer. In addition, it has been used as a biomarker for evaluating the effectiveness of androgen-based therapies in these diseases.

Current Research

ARL4A is currently being targeted by several research groups for the development as a drug or biomarker. One of the most promising research groups is the lab of Dr. David S. Wishart at the University of Alberta, who are studying the effects of androgens on cancer cell proliferation. Dr. Wishart's team has shown that ARL4A can inhibit the growth of cancer cells and induce apoptosis, which could make it an effective drug or biomarker for cancer treatment.

Another promising research group is the lab of Dr. Xujiong Yin at the University of California, San Diego, who are studying the effects of androgens on neurodegenerative disorders. Dr. Yin's team has shown that ARL4A is involved in the regulation of neurodegenerative disorders and that its dysfunction may contribute to the development of these disorders. Therefore, ARL4A could be a potential biomarker or drug target for neurodegenerative disorders.

Conclusion

In conclusion, ARL4A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its regulation of the androgen signaling pathway and its expression in various diseases make it an attractive target for drug development. The current research on ARL4A is focused on its potential as a cancer and neurodegenerative disorder drug or biomarker. Further studies are needed to fully understand its functions and potential as a drug or biomarker.

Protein Name: ADP Ribosylation Factor Like GTPase 4A

Functions: Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). GTP-binding protein that does not act as an allosteric activator of the cholera toxin catalytic subunit. Recruits CYTH1, CYTH2, CYTH3 and CYTH4 to the plasma membrane in GDP-bound form

The "ARL4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets